325 related articles for article (PubMed ID: 24577803)
1. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
[TBL] [Abstract][Full Text] [Related]
5. Selection criteria for lung-cancer screening.
Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
[TBL] [Abstract][Full Text] [Related]
6. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
8. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
[TBL] [Abstract][Full Text] [Related]
9. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
10. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.
Ten Haaf K; van Rosmalen J; de Koning HJ
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):154-61. PubMed ID: 25312998
[TBL] [Abstract][Full Text] [Related]
13. The performance of NLST screening criteria in Asian lung cancer patients.
Kumar V; Becker K; Zheng HX; Huang Y; Xu Y
BMC Cancer; 2015 Nov; 15():916. PubMed ID: 26582178
[TBL] [Abstract][Full Text] [Related]
14. Deep Learning to Assess Long-term Mortality From Chest Radiographs.
Lu MT; Ivanov A; Mayrhofer T; Hosny A; Aerts HJWL; Hoffmann U
JAMA Netw Open; 2019 Jul; 2(7):e197416. PubMed ID: 31322692
[TBL] [Abstract][Full Text] [Related]
15. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y
Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253
[TBL] [Abstract][Full Text] [Related]
17. Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network.
Petousis P; Han SX; Aberle D; Bui AA
Artif Intell Med; 2016 Sep; 72():42-55. PubMed ID: 27664507
[TBL] [Abstract][Full Text] [Related]
18. Performance of the cancer risk management model lung cancer screening module.
Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
[TBL] [Abstract][Full Text] [Related]
19. Improving selection criteria for lung cancer screening. The potential role of emphysema.
Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
[TBL] [Abstract][Full Text] [Related]
20. Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
Hendrick RE; Smith RA
Cancer; 2024 Jan; 130(2):216-223. PubMed ID: 37909872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
